CAMP Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 8.55%, SMA50 -11.15%, SMA200 42.57%). The stock’s 14-day RSI is 51.07 (neutral), while the ATR of 0.56 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -38.54% below its high and over 244.06% above its low. Average 10-day trading volume of 40.82 thousand shares is below the 3-month average of 147.03 thousand, indicating normal recent market interest.

CAMP4 Therapeutics Corporation has 20.16 million shares outstanding. The public float is 3.25 million shares, elevated short interest at 3.92% of float. This equals 221.46 thousand shares. The short ratio is 2.27 days. Institutional investors hold 79.76% of the float. Insiders own 35.1%. Cummins Wes holds 3.42 million shares, 5AM Partners VI, LLC has 2.94 million shares and B. Riley Asset Management, LLC has 2.23 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Wall Street analysts project EPS growth of 57.49% annually over the next five years. The latest quarter delivered EPS of -$0.55. The next quarter is forecast at -$0.30. Next year's EPS is expected at $871.44. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 0 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $12.00 to $7.00. The high target offers 204.57% upside. The low target suggests 77.66% downside. The mean target is $9.50. This offers 141.12% upside. CAMP4 Therapeutics Corporation earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by 17.02%. The prior quarter beat by -7.46%. Over the last six quarters, Apple has recorded several small beats. These include 2160.75% in October 11, 2024.

CAMP4 Therapeutics Corporation last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.41. This means the shares are trading above this model’s fair value.

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) closed at $3.94 USD, losing -$0.48 (-10.87%) from the previous close of $4.42. The stock is currently mid-range between its 52-week high and low $1.30 and $7.30. With a market capitalization of about $83.58 million, CAMP4 Therapeutics Corporation is classified as a micro-cap and shows lower-than-market volatility (beta ~0.36). Key stats such as the average daily volume over the past year has been around 160.12 thousand shares, volume is running light vs its 52-week average. Headquartered in Cambridge, MA, CAMP4 Therapeutics Corporation operates in the Healthcare sector and the Biotechnology industry. Led by CEO Joshua Mandel-Brehm, the company employs approximately 55 people and listed since October 11, 2024. CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients.

CAMP4 Therapeutics Corporation (NASDAQ:CAMP) shares are down -27.57% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows CAMP4 Therapeutics Corporation trading at a premium to the broader market with a P/E of -1.5. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $9.94, suggesting 152.28% upside. Our AI forecast model points to short-term weakness (-1.52% over two weeks), a medium-term fall (-85.28% over three months), and a longer-term gain (385.53% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that CAMP4 Therapeutics Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.52%, with price expected at $3.88 by March 17, 2026, within a range of $3.06 to $4.73 3-Month Outlook: Projected fall of -85.28%, reaching $0.58 by June 01, 2026, with a range of $0.28 to $0.84. 1-Year Outlook: Projected gain of 385.53%, with price at $19.13 by March 03, 2027, within a range of $1.61 to $19.23.

CAMP4 Therapeutics Corporation trades at a P/E ratio of -1.5, slightly below the S&P 500 average, with a price-to-sales ratio of 22.23 and a price-to-book ratio of 1.37 suggesting the stock is closer to book value. The P/FCF stands at -1.77, also below market averages.